Genaera Liquidating Trust (MEDI-528) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Genaera Liquidating Trust (MEDI-528) General Information

Description

A portfolio of intellectual property rights. The portfolio includes certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by AstraZeneca's subsidiary, MedImmune.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Commercial Products
Acquirer
Ligand Pharmaceuticals
Primary Office
  • 5110 Campus Drive
  • Plymouth Meeting, PA 19462
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Genaera Liquidating Trust (MEDI-528) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Genaera Liquidating Trust (MEDI-528)‘s full profile, request access.

Request a free trial

Genaera Liquidating Trust (MEDI-528) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Genaera Liquidating Trust (MEDI-528)‘s full profile, request access.

Request a free trial